Australia markets close in 3 hours 21 minutes

Kezar Life Sciences Inc (2KZ.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.6950+0.0050 (+0.72%)
At close: 07:08PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
7,000
0
0
0
-
Operating expenses
Research development
45,931
85,697
51,009
38,935
30,981
-
Selling general and administrative
19,300
26,540
20,153
15,724
11,969
-
Total operating expenses
65,231
112,237
71,162
54,659
42,950
-
Operating income or loss
-65,231
-105,237
-71,162
-54,659
-42,950
-
Interest expense
995
1,550
1,185
159
0
-
Total other income/expenses net
-
-6,187
-
-
-
-
Income before tax
-64,270
-101,870
-68,239
-54,630
-41,742
-
Income from continuing operations
-64,270
-101,870
-68,239
-54,630
-41,742
-
Net income
-64,270
-101,870
-68,239
-54,630
-41,742
-
Net income available to common shareholders
-64,270
-101,870
-68,239
-54,630
-41,742
-
Basic EPS
-1.21
-
-1.01
-1.04
-0.95
-1.84
Diluted EPS
-1.21
-
-1.01
-1.04
-0.95
-1.84
Basic average shares
72,440
-
67,369
52,759
44,004
19,084
Diluted average shares
72,440
-
67,369
52,759
44,004
19,084